Incretin-based pharmacotherapy has been suggested to be correlated with increased risk of AP in T2DM patients (Azoulay et al., 2016; Ueberberg et al., 2016; Tseng et al., 2017) although more recent and thorough studies have suggested that incretin-based treatment does not increase pancreatitis risk (Wang et al., 2015, 2018; Abd El Aziz et al., 2020). This evidence concerns the gene GCG and type 2 diabetes mellitus.